Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Jan 9, 2026--

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109621764/en/

The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.

“This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Based on the preclinical research conducted to date, we believe that the combination of Biocytogen’s RenLite ® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific ADCs.”

“This option-based framework allows us to systematically assess how dual-payload conjugation strategies can be applied to bispecific antibody formats,” said Sonny Hsiao, Ph.D., Chairman and CEO of Acepodia. “This collaboration reflects our focus on disciplined, data-driven AD2C platform expansion.”

The expanded partnership is intended to leverage complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia’s internal governance and option exercise criteria.

About Biocytogen

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

Biocytogen has independently developed its proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® /RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

About Acepodia

Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. Acepodia’s conjugation platforms are designed for modular integration across antibodies, immune cells, and payload architectures, enabling flexible application across diverse therapeutic modalities. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

WASHINGTON (AP) — U.S. forces boarded another oil tanker in the Caribbean Sea on Friday, the U.S. military said, as the Trump administration targets sanctioned tankers traveling to and from Venezuela as part of a broader effort to take control of the South American country's oil.

The predawn raid was carried out by Marines and Navy sailors launched from the aircraft carrier USS Gerald R. Ford, part of the extensive force the U.S. has built up in the Caribbean in recent months, according to U.S. Southern Command, which declared “there is no safe haven for criminals” as it announced the seizure of the tanker called the Olina. The Coast Guard then took control of the vessel, officials said.

Southern Command and Homeland Security Secretary Kristi Noem both posted unclassified footage on social media Friday morning of a U.S. helicopter landing on the vessel and U.S. personnel conducting a search of the deck and tossing what appeared to be an explosive device in front of a door leading to inside the ship.

In her post, Noem said the ship was “another ‘ghost fleet’ tanker ship suspected of carrying embargoed oil” and it had departed Venezuela “attempting to evade U.S. forces."

The Olina is the fifth tanker that has been seized by U.S. forces as part of the effort by President Donald Trump’s administration to control the production, refining and global distribution of Venezuela’s oil products, and the third since the U.S. ouster of Venezuela President Nicolás Maduro in a surprise nighttime raid.

In a post on his social media network later in the day, Trump said the seizure was conducted “in coordination with the Interim Authorities of Venezuela” but offered no elaboration.

The White House did not immediately respond to requests for more details.

Venezuela’s government acknowledged in a statement that it was working with U.S. authorities to return the tanker, “which set sail without payment or authorization from the Venezuelan authorities,” to the South American nation.

“Thanks to this first successful joint operation, the ship is sailing back to Venezuelan waters for its protection and relevant actions,” according to the statement.

Samir Madani, co-founder of TankerTrackers.com, said his organization used satellite imagery and surface-level photos to document that at least 16 tankers left the Venezuelan coast in contravention of the quarantine U.S. forces have set up to block sanctioned ships from conducting trade. The Olina was among that flotilla.

U.S. government records show that the Olina was sanctioned for moving Russian oil under its prior name, Minerva M, and flagged in Panama.

While records show the Olina is now flying the flag of Timor-Leste, it is listed in the international shipping registry as having a false flag, meaning the registration it is claiming is not valid. In July, the owner and manager of the ship on its registration was changed to a company in Hong Kong.

According to ship tracking databases, the Olina last transmitted its location in November in the Caribbean, north of the Venezuelan coast. Since then, however, the ship has been running dark with its location beacon turned off.

While Noem and the military framed the seizure as part of an effort to enforce the law, other officials in the Trump administration have made clear they see it as a way to generate cash as they seek to rebuild Venezuela's battered oil industry and restore its economy.

In an early morning social media post, Trump said the U.S. and Venezuela “are working well together, especially as it pertains to rebuilding, in a much bigger, better, and more modern form, their oil and gas infrastructure.”

The administration said it expects to sell 30 million to 50 million barrels of sanctioned Venezuelan oil, with the proceeds to go to both the U.S. and Venezuelan people. But the president expects the arrangement to continue indefinitely. He met Friday with executives from oil companies to discuss his goal of investing $100 billion in Venezuela to repair and upgrade its oil production and distribution.

Vice President JD Vance told Fox News this week that the U.S. can “control” Venezuela’s “purse strings” by dictating where its oil can be sold.

Madani estimated that the Olina is loaded with 707,000 barrels of oil, which at the current market price of about $60 a barrel would be worth more than $42 million.

Associated Press writers Dánica Coto in San Juan, Puerto Rico, Josh Boak in Washington, and Regina Garcia Cano in Caracas, Venezuela, contributed to this report.

This story has been corrected to reflect that the United States has seized three tankers, not five, since Nicolás Maduro was ousted as Venezuela’s president.

FILE - Evana, an oil tanker, is docked at El Palito Port in Puerto Cabello, Venezuela, Dec. 21, 2025. The U.S. military says U.S. forces have boarded another oil tanker in the Caribbean Sea. The Olina is the fifth tanker seized by U.S. forces. (AP Photo/Matias Delacroix, File)